Literature DB >> 33007232

Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes.

Jeffrey A Bluestone1, Qizhi Tang2.   

Abstract

Type 1 diabetes mellitus results from autoimmune destruction of pancreatic β cells. Insulin treatment is often inadequate in preventing devastating complications. Replacing β cells using stem cell-derived islets while fostering immune tolerance, exemplified in Yoshihara et al., holds the promise of a curative therapy for this disease.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2020        PMID： 33007232     DOI： 10.1016/j.stem.2020.09.008

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  5 in total

Review 1.  Engineering islets from stem cells for advanced therapies of diabetes.

Authors:  Johanna Siehler; Anna Karolina Blöchinger; Matthias Meier; Heiko Lickert
Journal:  Nat Rev Drug Discov       Date:  2021-08-10       Impact factor: 84.694

Review 2.  Transforming type 1 diabetes: the next wave of innovation.

Authors:  Daniel J Drucker
Journal:  Diabetologia       Date:  2021-02-06       Impact factor: 10.122

Review 3.  The promise of stem cell-derived islet replacement therapy.

Authors:  Douglas Melton
Journal:  Diabetologia       Date:  2021-01-16       Impact factor: 10.122

Review 4.  The progress of pluripotent stem cell-derived pancreatic β-cells regeneration for diabetic therapy.

Authors:  Xin Wang; Mengxi Gao; Yali Wang; Yucheng Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

Review 5.  Bioengineering the Vascularized Endocrine Pancreas: A Fine-Tuned Interplay Between Vascularization, Extracellular-Matrix-Based Scaffold Architecture, and Insulin-Producing Cells.

Authors:  Cataldo Pignatelli; Francesco Campo; Alessia Neroni; Lorenzo Piemonti; Antonio Citro
Journal:  Transpl Int       Date:  2022-08-25       Impact factor: 3.842
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.